FATE logo

FATE
Fate Therapeutics Inc

6,426
Mkt Cap
$177.88M
Volume
5.13M
52W High
$1.94
52W Low
$0.91
PE Ratio
-1.33
FATE Fundamentals
Price
$1.53
Prev Close
$1.25
Open
$1.25
50D MA
$1.29
Beta
1.65
Avg. Volume
1.18M
EPS (Annual)
-$1.15
P/B
0.85
Rev/Employee
$41,279.50
$9.08
Loading...
Loading...
News
all
press releases
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average recommendation of "Hold" from the eight research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold rec...
MarketBeat·16d ago
News Placeholder
More News
News Placeholder
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference
Fate Therapeutics (NASDAQ:FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing off-the-shelf CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. Preside...
MarketBeat·17d ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) Stock Passes Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Scalable Biotech Manufacturing Unlocks a $14B Market
Scalable Biotech Manufacturing Unlocks a $14B Market Scalable Biotech Manufacturing Unlocks a $14B Market PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of Ava Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary The global cell therapy manufacturing...
PR Newswire·1mo ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have...
MarketBeat·1mo ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 9,563,527...
MarketBeat·2mo ago
News Placeholder
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company's clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside...
MarketBeat·2mo ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts...
MarketBeat·2mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Earnings Summary: Fate Therapeutics Q4
read more...
Benzinga·2mo ago
<
1
2
...
>

Latest FATE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.